Tumor Lysis Syndrome: Incidence, Mitigation and Management in Patients with Chronic Lymphocytic Leukemia Initiating Venetoclax in Routine Clinical Practice (DEVOTE) across Canada
Blood(2021)
摘要
Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) receiving venetoclax (VEN) are at risk of tumor lysis syndrome (TLS). This may be mitigated by implementing a 5-week ramp-up dosing schedule, use of antiuricemic agents and continuous hydration in high-risk patients. Currently, there is a lack of real-world data on the incidence of TLS in routine clinical care of R/R CLL patients treated with VEN in Canada. This is particularly the case amongst heavily pretreated patients progressing on prior ibrutinib who would be considered at high risk for aggressive disease and subsequent TLS.
更多查看译文
关键词
tumor lysis syndrome,leukemia
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要